120 related articles for article (PubMed ID: 20210915)
21. Diabetes under control: Understanding oral antidiabetic agents.
Longo R
Am J Nurs; 2010 Feb; 110(2):49-52. PubMed ID: 20107402
[No Abstract] [Full Text] [Related]
22. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2013 May; 9(5):529-50. PubMed ID: 23461781
[TBL] [Abstract][Full Text] [Related]
23. Optimal medication dosing in patients with diabetes mellitus and chronic kidney disease.
MacCallum L
Can J Diabetes; 2014 Oct; 38(5):334-43. PubMed ID: 25284697
[TBL] [Abstract][Full Text] [Related]
24. New oral agents for type II diabetes. Taking a more aggressive approach to therapy.
Hollander PA
Postgrad Med; 1995 Dec; 98(6):110-1, 115-6, 119-21, passim. PubMed ID: 7501573
[TBL] [Abstract][Full Text] [Related]
25. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
26. Management of drugs affecting blood glucose in diabetic patients with renal failure.
Charpentier G; Riveline JP; Varroud-Vial M
Diabetes Metab; 2000 Jul; 26 Suppl 4():73-85. PubMed ID: 10922977
[TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification.
McGill JB
Curr Diabetes Rev; 2012 Jul; 8(4):257-67. PubMed ID: 22515702
[TBL] [Abstract][Full Text] [Related]
28. Incretins: the novel therapy of type 2 diabetes.
Thongtang N; Sriwijitkamol A
J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
[TBL] [Abstract][Full Text] [Related]
29. Glycemic control and treatment patterns in patients with heart failure.
Tang WH
Heart Fail Monit; 2006; 5(1):10-4. PubMed ID: 16547530
[TBL] [Abstract][Full Text] [Related]
30. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
31. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
32. [Chronic kidney disease and antidiabetic treatment].
Berwert L; Teta D; Zanchi A
Rev Med Suisse; 2007 Mar; 3(101):598-604. PubMed ID: 17436798
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
Manolopoulos VG; Ragia G; Tavridou A
Pharmacogenomics; 2011 Aug; 12(8):1161-91. PubMed ID: 21843065
[TBL] [Abstract][Full Text] [Related]
34. [Effectiveness of oral hypoglycemic drugs in the metabolic control of patients with gestational diabetes].
Valdés R E; Soto-Chacón E; Lahsen M R; Barrera H C; Candía P P
Rev Med Chil; 2008 Jul; 136(7):915-20. PubMed ID: 18949170
[TBL] [Abstract][Full Text] [Related]
35. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
36. [Approach to diabetic therapy. 2. Selection and the use of oral antidiabetics. 3) Biguanides and alpha-glucosidase inhibitors].
Onuma T
Nihon Naika Gakkai Zasshi; 2000 Aug; 89(8):1536-43. PubMed ID: 11062901
[No Abstract] [Full Text] [Related]
37. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.
Marchetti P; Navalesi R
Clin Pharmacokinet; 1989 Feb; 16(2):100-28. PubMed ID: 2656043
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic optimisation of oral hypoglycaemic therapy.
Marchetti P; Giannarelli R; di Carlo A; Navalesi R
Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902
[TBL] [Abstract][Full Text] [Related]
39. [Oral antidiabetic drugs in chronic renal disease].
Somogyi A
Orv Hetil; 2012 Nov; 153(44):1727-31. PubMed ID: 23103741
[TBL] [Abstract][Full Text] [Related]
40. Diabetes mellitus and kidney disease in the elderly.
Iglesias P; Heras M; Díez JJ
Nefrologia; 2014 May; 34(3):285-92. PubMed ID: 24798557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
